FDA Decisions Loom for Biotech Stocks in September 2025

The FDA is set to make decisions on several biotech and pharmaceutical drug candidates in September 2025. This month marks several observances, including World Alzheimer's Month and Blood Cancer Awareness Month. So far this year, the FDA has approved 26 novel drugs, slightly fewer than the 29 approvals recorded during the same period last year.

September 2025 is set to be a pivotal month for the biotech and pharmaceutical industries, with several key drug candidates poised for FDA decisions. This period coincides with significant health awareness campaigns, including World Alzheimer's Month and Blood Cancer Awareness Month. The FDA has approved 26 novel drugs so far this year, a slight decrease from the 29 approvals recorded in the same period last year.

Biotech Stocks to Watch

Several biotech stocks are expected to release critical clinical trial data in September, which could significantly impact their stock prices. Here are some key companies to watch:

1. KALA BIO Inc. (KALA) - KALA is expected to release topline data from its CHASE trial of KPI-012 by the end of September 2025. The CHASE trial is a Phase 2b study evaluating KPI-012, a topical biologic therapy for persistent corneal epithelial defect (PCED). If the results are positive, this could be the first of two pivotal trials supporting a Biologics License Agreement for KPI-012 with the FDA.

2. Kairos Pharma Ltd. (KAPA) - Kairos is scheduled to report interim efficacy data from its Phase 2 trial of ENV-105 in patients with metastatic castration-resistant prostate cancer in September. The trial is designed to enroll 100 patients and has already demonstrated positive safety results.

3. Rapport Therapeutics Inc. (RAPP) - Rapport is on track to release topline results from its Phase 2a trial of investigational drug RAP-219 in patients with drug-resistant focal onset seizures in September 2025. The upcoming data analysis will focus on the primary endpoint, key secondary endpoint, and safety of the treatment.

4. Metsera Inc. (MTSR) - Metsera is expected to report key findings from two studies under its VESPER program in September 2025. The VESPER program includes three ongoing Phase 2b trials evaluating MET-097i for the treatment of obesity and overweight.

5. Cullinan Therapeutics Inc. (CGEM) - Cullinan is developing Zipalertinib, a drug for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutation. Initial data from the REZILIENT2 cohort exploring Zipalertinib will be presented at the IASLC 2025 WCLC in September.

Market Implications

The FDA's decisions in September could have significant market implications. Positive results from these trials could drive investor interest and stock price appreciation, while negative results could lead to stock price declines. Additionally, the approval of novel drugs could influence market competition, pricing strategies, and regulatory outcomes.

Regulatory Landscape

The FDA's approval process is rigorous, with a focus on clinical efficacy, safety, and long-term monitoring. The agency has approved 26 novel drugs this year, slightly fewer than the 29 approvals in the same period last year. The FDA's decisions in September will contribute to this year's total, which could influence the overall trend in drug approvals.

Conclusion

September 2025 is a critical month for biotech and pharmaceutical companies, with several key drug candidates awaiting FDA decisions. Investors and financial professionals should closely monitor these developments, as they could significantly impact stock prices and market dynamics. The FDA's decisions will also shape the future of obesity care, with the potential for oral GLP-1 therapies to reshape the treatment landscape.

References

[1] https://www.geneonline.com/eli-lillys-oral-glp-1-weight-loss-pill-clears-third-phase-3-trial-bringing-fda-approval-within-reach/
[2] https://www.rttnews.com/3569385/5-biotech-stocks-to-watch-ahead-of-major-clinical-trial-data-readouts-in-september-2025.aspx